Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lemborexant

FDA-approved product (tablet, oral), marketed as Dayvigo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lemborexant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Orexin receptor antagonists
FDA pharmacologic class
Orexin Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lemborexant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lemborexant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Lemborexant for Cannabis Use Disorder

    NCT07802990 · start 2026-11

    Registered record
    Registry ID
    NCT07802990
    Conditions
    Cannabis Use Disorder
    Interventions
    Lemborexant 10mg; Placebo; Brief Behavioural Intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2028-11
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabis Use Disorder
    InterventionLemborexant 10mg; Placebo; Brief Behavioural Intervention
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Lemborexant on Perioperative Sleep Quality in Patients Undergoing Thoracoscopic Surgery

    NCT07811401 · start 2026-10-08

    Registered record
    Registry ID
    NCT07811401
    Conditions
    Postoperative Sleep Disturbance; Thoracoscopic Surgery
    Interventions
    Lemborexant 5 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-08
    Completion
    2028-06-01
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Sleep Disturbance; Thoracoscopic Surgery
    InterventionLemborexant 5 mg; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • The Optimal One-Month Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patients With Low Arousal Threshold

    NCT07683442 · start 2026-09-01

    Registered record
    Registry ID
    NCT07683442
    Conditions
    OSA - Obstructive Sleep Apnea
    Interventions
    Lemborexant 5 MG [Dayvigo] Period 1; Placebo Period 1; Lemborexant 5 MG [Dayvigo] Period 2; Placebo Period 2; Lemborexant 5 MG [Dayvigo] Period 3; Placebo Period 3; Lemborexant 10 MG [Dayvigo] Period 1; Lemborexant 10 MG [Dayvigo] Period 2; Lemborexant 10 MG [Dayvigo] Period 3
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2028-06-30
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOSA - Obstructive Sleep Apnea
    InterventionLemborexant 5 MG [Dayvigo] Period 1; Placebo Period 1; Lemborexant 5 MG [Dayvigo] Period 2; Placebo Period 2 +5 more
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Lemborexant Use for Cognition Improvement in Postoperative Delirium in Elderly Patients: A Randomized Controlled Trial

    NCT07695285 · start 2026-09-01

    Registered record
    Registry ID
    NCT07695285
    Conditions
    Postoperative Delirium
    Interventions
    Lemborexant Pill; Placebo tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2029-12-31
    Enrolment
    992

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Delirium
    InterventionLemborexant Pill; Placebo tablet
    PhasePhase 2
    Registry statusNot yet recruiting

  • Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease

    NCT07384429 · start 2026-08-19

    Registered record
    Registry ID
    NCT07384429
    Conditions
    Parkinson's Disease; Insomnia; Motor Disorder
    Interventions
    Lemborexant; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-19
    Completion
    2026-12-01
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease; Insomnia; Motor Disorder
    InterventionLemborexant; placebo
    PhasePhase 4
    Registry statusNot yet recruiting

  • Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients

    NCT07407400 · start 2026-04-01

    Registered record
    Registry ID
    NCT07407400
    Conditions
    Sleep Disturbance; Delirium; Critical Illness
    Interventions
    Lemborexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04-01
    Completion
    2027-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Disturbance; Delirium; Critical Illness
    InterventionLemborexant; Placebo
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders

    NCT07417813 · start 2026-01-24

    Registered record
    Registry ID
    NCT07417813
    Conditions
    Insomnia; Psychiatric Disorders
    Interventions
    Lemborexant tablets
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-01-24
    Completion
    2026-12-31
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Psychiatric Disorders
    InterventionLemborexant tablets
    PhaseNot recorded
    Registry statusRecruiting

  • Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping

    NCT06928766 · start 2025-10-31

    Registered record
    Registry ID
    NCT06928766
    Conditions
    OSA - Obstructive Sleep Apnea
    Interventions
    Eszopiclone 3 mg; Placebo; Lemborexant 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-31
    Completion
    2027-06-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOSA - Obstructive Sleep Apnea
    InterventionEszopiclone 3 mg; Placebo; Lemborexant 10mg
    PhasePhase 2
    Registry statusRecruiting

  • Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects

    NCT06981195 · start 2025-05-27

    Registered record
    Registry ID
    NCT06981195
    Conditions
    Opioid Use Disorder; Opioid Use; Insomnia; Orexin Antagonist
    Interventions
    Placebo; Lemborexant 10 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-27
    Completion
    2029-07-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; Opioid Use; Insomnia; Orexin Antagonist
    InterventionPlacebo; Lemborexant 10 MG
    PhasePhase 2
    Registry statusRecruiting

  • A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.

    NCT06823752 · start 2025-05-13

    Registered record
    Registry ID
    NCT06823752
    Conditions
    Insomnia
    Interventions
    Lemborexant 10 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-13
    Completion
    2027-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionLemborexant 10 MG; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients

    NCT06648681 · start 2025-05-01

    Registered record
    Registry ID
    NCT06648681
    Conditions
    Delirium - Postoperative; Cardiac Surgery; Cardiac Surgery Subjects; Orexin Antagonist; Feasibility Studies; Sleep; In-hospital Mortality
    Interventions
    Lemborexant 5 mg; Control (placebo) group
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2027-04-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium - Postoperative; Cardiac Surgery; Cardiac Surgery Subjects; Orexin Antagonist +3 more
    InterventionLemborexant 5 mg; Control (placebo) group
    PhasePhase 2
    Registry statusNot yet recruiting

  • Efficacy of CBT-I and Lemborexant Medication for Different Subtypes of Chronic Insomnia

    NCT06779149 · start 2025-04-01

    Registered record
    Registry ID
    NCT06779149
    Conditions
    Insomnia Disorder
    Interventions
    Cognitive Behavioral Treatment for Insomnia (CBT-I); Lemborexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-04-01
    Completion
    2027-02
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia Disorder
    InterventionCognitive Behavioral Treatment for Insomnia (CBT-I); Lemborexant; Placebo
    PhaseNot applicable
    Registry statusRecruiting

  • A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population

    NCT06744673 · start 2025-01-03

    Registered record
    Registry ID
    NCT06744673
    Conditions
    Sleep Initiation and Maintenance Disorders; Pregnancy
    Interventions
    No Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-01-03
    Completion
    2025-12-30
    Enrolment
    861

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Initiation and Maintenance Disorders; Pregnancy
    InterventionNo Intervention
    PhaseNot recorded
    Registry statusActive not recruiting

  • Lemborexant Treatment of Insomnia Linked to Epilepsy

    NCT06262594 · start 2024-10-29

    Registered record
    Registry ID
    NCT06262594
    Conditions
    Epilepsy; Sleep
    Interventions
    Lemborexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-10-29
    Completion
    2027-04-18
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy; Sleep
    InterventionLemborexant; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems

    NCT07480096 · start 2024-10-01

    Registered record
    Registry ID
    NCT07480096
    Conditions
    Cirrhosis; Liver Cirrhosis; Sleep Quality; Insomnia; Hepatic Encephalopathy
    Interventions
    Lemborexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-10-01
    Completion
    2025-10-30
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis; Liver Cirrhosis; Sleep Quality; Insomnia +1 more
    InterventionLemborexant; Placebo
    PhasePhase 2
    Registry statusCompleted